Amendment No. 4 to Schedule 13D for Vor Biopharma Inc.

This Amendment No. 4 to Schedule 13D, filed by Reprogrammed Interchange LLC and Reid Hoffman, updates the previously filed Schedule 13D. The amendment reports significant sales of Vor Biopharma Inc. Common Stock by Reprogrammed Interchange LLC from September 12, 2025, to October 3, 2025. The sales resulted in a decrease of more than one percent in the number of shares beneficially owned by the Reporting Persons. The transactions include sales of 15,000 shares on September 12, 2025, at a weighted average price of $35.0811, and 32,451 shares on October 2, 2025, at a weighted average price of $39.828, among others. The amendment also reflects the impact of a 1-for-20 reverse stock split of Vor Biopharma Inc. Common Stock effected on September 18, 2025. The Reporting Persons collectively own 23.3% of the outstanding shares of Common Stock of the Issuer.